Clinical impact and predisposing factors of delayedonset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: Association with an incremental risk of infectious events

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1699-1705

  Kato, H ^a   Yamamoto, K ^a   Matsuo, K ^a   Oki, Y ^a   Taji, H ^a   Kuwatsuka, Y ^a   Seto, M ^a   Kagami, Y ^a   Morishima, Y ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Immunotherapy; Neutropenia; Rituximab; Toxicity; Viral infection

Indexed keywords

CLADRIBINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; FEMALE; FOLLICULAR LYMPHOMA; GASTROENTERITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VARICELLA ZOSTER VIRUS; WHOLE BODY RADIATION;

EID: 77955254473     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq008     Document Type: Article

References (30)

1. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
2. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
3. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
4. Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18: 3135-3143.
5. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
6. Flinn IW, O'Donnell PV, Goodrich A et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-632.
7. Gianni AM, Magni M, Martelli M et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749-755.
8. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous haematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.
9. Kato H, Taji H, Ogura M et al. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma 2009; 9: 443-446.
10. van Heeckeren WJ, Vollweiler J, Fu P et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132: 42-55.
11. Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691-2694.
12. Chaiwatanatorn K, Lee N, Grigg A et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-918.
13. Cairoli R, Grillo G, Tedeschi A et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89: 361-363.
14. Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921-923.
15. Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: 364-369.
16. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995; 24: 183-187.
17. Papadaki T, Stamatopoulos K, Stavroyianni N et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26: 597-600.
18. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
19. Rios-Fernández R, Gutierrez-Salmerón MT, Callejas-Rubio JL et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007; 157: 1271-1273.
20. Marotte H, Paintaud G, Watier H et al. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 893-894.
21. Bouaziz JD, Yanaba K, Venturi GM et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 2007; 104: 20878-20883.
22. Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
23. Kasamon YL, Jones RJ, Brodsky RA et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 2010; 21(6): 1203-1210.
24. Leseux L, Laurent G, Laurent C et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285-291.
25. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in hemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-3636.
26. Dunleavy K, Hakim F, Kim HK et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106: 795-802.
27. Terrier B, Ittah M, Tourneur L et al. Late-onset neutropenia following rituximab results from a haematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007; 92: e20-e23.
28. Christopeit M, Haak U, Behre G. Late-onset neutropenia following viral bone marrow depression after rituximab therapy. Ann Hematol 2008; 87: 761-762.
29. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 2008; 35: 1245-1255.
30. El Fassi D, Nielsen CH, Hasselbalch HC et al. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006; 154: 623-632.